[ij] [ij] [ij] 
Email id

Asian Journal of Research in Pharmaceutical Science
Year : 2016, Volume : 6, Issue : 1
First page : ( 34) Last page : ( 36)
Print ISSN : 2231-5640. Online ISSN : 2231-5659.
Article DOI : 10.5958/2231-5659.2016.00005.9

A Review on New Antihypertensive Agent: Irbesartan

Paras Virani1,2,*, Kinjal Virani

1Research Scholar 2014, Gujarat Technological University, Gujarat

2Quality assurance department, Shree Dhanvantary Pharmacy College, Kim, Surat

*Corresponding Author E-mail: parasvirani@gmail.com

Online published on 2 April, 2016.


Hypertension is currently measure disorder obtain in the world population. Irbesartan is classified as an angiotensin II receptor type 1 antagonist. Angiotensin II receptor type 1 antagonists are widely used in treatment of diseases like hypertension, heart failure, myocardial infarction and diabetic nephropathy. The clinical and pharmacological analysis of this drug gives idea about effectivity of this drug in hypertension condition. Irbesartan act on renin angiotensin system and decreases biding of angiotensin to the receptor so decreases the blood pressure and act as an antihypertensive agent. Irbesartan is tetrazole derivative which selectively inhibit or antagonise the angiotensin type II receptor. In this review gives detail about mechanism of action of irbesartan in hypertension.



Irbesartan, hypertension, anti hypertensive drug, angiotensin ii receptor antagonist.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
671,587,309 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.